How is IGF-1 LR3 administered?
This describes how IGF-1 LR3 is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a daily schedule, generally over 4 weeks max, well-spaced breaks. Specific dosing is individual and beyond general information, and human evidence for IGF-1 LR3 is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Daily
- Cycle length: 4 weeks max, well-spaced breaks
- Half-life: ~20-30 hours
References
- IGF-I and its analogs in clinical use — Clemmons DR, Endocrinol Metab Clin North Am, 2012
- Detection of His-tagged Long-R3-IGF-I in a black market product — Kohler M, Thomas A, Walpurgis K, et al., Growth Hormone & IGF Research, 2010
- Site-specific fluorescent derivatization and liquid chromatographic-mass spectrometric characterization of long R(3) IGF-I for bioanalytical applications — Harvey MD, Banks PR, Journal of Chromatography B, 2003
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on IGF-1 LR3
Last updated 2026-06-15.